Skip to main content

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,
tomorrow, Tuesday, October 4

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD). Following the press release, the Company will host a webcast and conference call at 5:30 a.m. PDT to discuss these results.

The news release will be posted to the investor relations section of Connect Biopharma’s website at: https://investors.connectbiopharm.com/investors.

About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/

IR/PR CONTACTS: 
Ina McGuinness
T: +1 (805) 427-1372
imcguinness@connectpharm.com

 


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.11
-4.92 (-2.22%)
AAPL  255.99
-6.78 (-2.58%)
AMD  225.87
-12.16 (-5.11%)
BAC  50.55
-0.97 (-1.87%)
GOOG  251.19
-0.15 (-0.06%)
META  725.10
-8.17 (-1.11%)
MSFT  518.58
+0.92 (0.18%)
NVDA  177.62
-3.54 (-1.95%)
ORCL  271.18
-3.97 (-1.44%)
TSLA  431.50
-11.10 (-2.51%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.